Revolution Medicines, Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Revolution Medicines, Inc. (RVMD)
CIK: 0001628171
Period of Report: 2021-02-05

Reporting Person: GOLDSMITH MARK A (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-05	Common Stock	M	15000	$1.12	Acquired	15744	Direct
2021-02-05	Common Stock	S	15000	$55	Disposed	744	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-05	Stock Option (Right to Buy)	$1.12	M	15000	Disposed	2028-04-19	Common Stock (15000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	35953	Indirect
Common Stock	35953	Indirect
Common Stock	247093	Indirect

Footnotes

F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2: Includes 744 shares acquired under the Issuer's Employee Stock Purchase Plan on November 30, 2020.

F3: Held by Jonathan Henry Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

F4: Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

F5: Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

F6: This option is early exercisable. One forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary measured from March 29, 2018 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.